Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.63 |
| ▸ | RAB9A | P51151 | 5/20 | 0.63 |
| ▸ | NPC1 | O15118 | 4/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | EGFR | P00533 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15255707 | 0.85 | RAB9A (0.63) | ALDH1A1RAB9ANPC1SMN1; SMN2L3MBTL1 | |
| SCHEMBL1888991 | 0.82 | MAPT (0.69) | ALDH1A1RAB9ANPC1SMN1; SMN2L3MBTL1 | |
| SCHEMBL29128652 | 0.80 | RAB9A (0.61) | ALDH1A1RAB9ANPC1SMN1; SMN2L3MBTL1 | |
| SCHEMBL2625557 | 0.80 | MAPT (0.60) | ALDH1A1RAB9ANPC1SMN1; SMN2L3MBTL1 | |
| SCHEMBL10172936 | 0.80 | ALDH1A1 (0.58) | ALDH1A1RAB9ANPC1SMN1; SMN2L3MBTL1 | |
| SCHEMBL2605852 | 0.80 | ALDH1A1 (0.58) | ALDH1A1RAB9ANPC1SMN1; SMN2L3MBTL1 | |
| SCHEMBL1430419 | 0.80 | MAPT (0.67) | ALDH1A1RAB9ANPC1SMN1; SMN2L3MBTL1 | |
| SCHEMBL5803752 | 0.78 | MAPT (0.65) | ALDH1A1RAB9ANPC1SMN1; SMN2L3MBTL1 | |
| SCHEMBL172042 | 0.78 | MAPT (0.65) | ALDH1A1RAB9ANPC1SMN1; SMN2L3MBTL1 | |
| SCHEMBL171882 | 0.78 | MAPT (0.70) | ALDH1A1RAB9ANPC1SMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114867525-A | Dihydrocyclopentaisoquinoline derivatives | UCB生物制药有限责任公司 | 2022-08-05 | — | — | CN | claimed |
| CN-114867525-A | Dihydrocyclopentaisoquinoline derivatives | UCB生物制药有限责任公司 | 2022-08-05 | — | — | CN | disclosed |
| US-20170022150-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2017-01-26 | — | — | US | disclosed |
| US-20160332996-A1 | Hepatitis B Antiviral Agents | ENANTA PHARMACEUTICALS, INC. | 2016-11-17 | — | — | US | disclosed |
| US-9018378-B2 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | METHYLGENE INC. (CA) | 2015-04-28 | — | — | US | disclosed |
| US-8907091-B2 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | METHYLGENE INC. (CA) | 2014-12-09 | — | — | US | disclosed |
| US-8906852-B2 | Inhibitors of protein tyrosine kinase activity | METHYLGENE INC. (CA) | 2014-12-09 | — | — | US | disclosed |
| US-20140315801-A1 | METHODS OF TREATMENT OF CELL PROLIFERATIVE AND/OR OPHTHALMIC DISEASES, DISORDERS AND CONDITIONS USING INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC (CA) | 2014-10-23 | — | — | US | disclosed |
| US-8846927-B2 | Inhibitors of protein tyrosine kinase activity | METHYLGENE INC. (CA) | 2014-09-30 | — | — | US | disclosed |
| US-8569503-B2 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | METHYLGENE INC. (CA) | 2013-10-29 | — | — | US | disclosed |
| US-8404846-B2 | Inhibitors of protein tyrosine kinase activity | METHYLGENE INC. (CA) | 2013-03-26 | — | — | US | disclosed |
| US-8389541-B2 | Inhibitors of protein tyrosine kinase activity | METHYLGENE INC. (CA) | 2013-03-05 | — | — | US | disclosed |
| US-20120165313-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-8163763-B2 | Pyrimidine compounds, compositions and methods of use | GENENTECH, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20110130406-A1 | PYRAZOLO-PYRIDINES AS TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-06-02 | — | — | US | disclosed |
| US-20100331305-A1 | OXO-HETEROCYCLE FUSED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| EP-0000035-A1 | Alpha-amino acids, compositions and process for preparing said compounds | MERCK & CO. INC. (US) | 1978-12-20 | — | — | EP | disclosed |
| US-4116671-A | HERBICIDES | SHIONOGI & CO., LTD. (JP) | 1978-09-26 | — | — | US | disclosed |
| US-4111680-A | HERBICIDAL COMPOSITIONS CONTAINING 3-ISOXAZOLYLUREA DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 1978-09-05 | — | — | US | disclosed |
| US-4062861-A | HERBICIDE | SHIONOGI & CO., LTD. (JA) | 1977-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331305-A1 | OXO-HETEROCYCLE FUSED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | MTOR, PIK3CA, RICTOR | ALDH1A1 4645/4885RAB9A 1277/4885NPC1 2355/4885 |
| US-20170022150-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, ZC3HAV1, SLC10A1 | ALDH1A1 2749/4885RAB9A 1332/4885NPC1 607/4885 |
| US-20110130406-A1 | PYRAZOLO-PYRIDINES AS TYROSINE KINASE INHIBITORS | TYRO3, LCK, LTK | ALDH1A1 1744/4885RAB9A 2234/4885NPC1 3537/4885 |
| US-20120165313-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | MTOR, TYMS, DTYMK | ALDH1A1 4303/4885RAB9A 2119/4885NPC1 1811/4885 |
| US-20140315801-A1 | METHODS OF TREATMENT OF CELL PROLIFERATIVE AND/OR OPHTHALMIC DISEASES, DISORDERS AND CONDITIONS USING INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | FLT1, KDR, FLT4 | ALDH1A1 2750/4885RAB9A 1805/4885NPC1 3015/4885 |
| US-20160332996-A1 | Hepatitis B Antiviral Agents | ZC3HAV1, ZC3HAV1L, HAVCR2 | ALDH1A1 3457/4885RAB9A 1062/4885NPC1 472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.